RTTNews BiotechCodex · 实盘不做把握 6/10
北京时间·🕒 发布 23:14:25时区推断·⟳ 抓取 23:15:16·⚡ 决策 07-27 23:18:11 +2m55s·91.8 天前
诺诚健华ICP-488治疗中重度斑块状银屑病III期注册研究达到主要终点
事件本身是正面临床进展：ICP-488银屑病III期达到主要终点并拟推进注册申报，但仍未披露完整疗效数据、获批时间和商业化增量。
📄 原文RTTNews Biotech↗ 原文
InnoCare's Fadeucravacitinib Hits Phase III Goal In Psoriasis Trial
InnoCare Pharma (INCPF) announced that its novel TYK2 inhibitor, Fadeucravacitinib, achieved the primary endpoint in a…
不做 诺诚健华（688428.SH）
同一具体催化已在系统内多次处理且已有688428.SH的ENTER记录，本条RTTNews为后到转述；为避免重复推卡和重复下单，当前不做。
不做 诺诚健华（09969.HK）
同一发行人同一ICP-488银屑病III期主要终点事件已处理，且港股近20日已涨28.2%、消息已多源扩散；当前不重复开新腿。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- 诺诚健华发布英文稿，确认ICP-488银屑病III期注册研究达到主要终点。
- 中文财经媒体转述港股09969.HK自愿公告，并提示产品开发、上市及商业化仍有不确定性。
- 智通财经以688428.SH口径转述同一III期主要终点事件。市场反应:688428.SH当日收盘27.73元，涨0.18%；09969.HK收13.91港元，涨0.8%。
- RTTNews在美股盘中发布英文转述，晚于公司/GlobeNewswire及中文财经媒体扩散。
关键理由
- 事件本身是正面临床进展：ICP-488银屑病III期达到主要终点并拟推进注册申报，但仍未披露完整疗效数据、获批时间和商业化增量。
- 该催化在本系统近72小时内已多次处理，且案例库显示同一具体催化已有一条688428.SH的ENTER决策，当前RTTNews为后续转述，不应重复推卡。
- 商业化量级仍需等完整III期数据和申报节奏确认；公司当前主要收入来自已商业化产品，ICP-488尚未产生收入。
主要风险
- 若后续国际会议披露数据显著优于同类TYK2药物，可能形成新的可研判增量。
- 港股09969.HK近20日已涨28.2%，A股688428.SH盘后才可交易，重复追单的执行性价比低。
反向证据
- 做多前查反向 · 来源 stock_tools · 日期 2026-07-27 · 影响 invalidates
系统内近72小时/案例库已出现多条同一ICP-488银屑病III期主要终点决策，其中已有一条688428.SH的ENTER，当前不应重复推卡。
检索:search_processed_events hours=72 limit=200; search_case_library 688428.SH,09969.HK - 做多前查反向 · 来源 kb_search · 日期 2026-07-27 · 影响 weakens
KB未给出早于今日的III期成功旧闻，但命中同日研报/资讯环境，说明临床进展在医药圈已有跟踪。
检索:诺诚健华 ICP-488 三期 达到主要终点 2026-07-27 旧闻 原文 ↗
工具调用 · 历史记录,结果未知(6 种)
- search_processed_events · 结果未知
- normalize_ticker · 结果未知
- kb_search · 结果未知
- price_snapshot · 结果未知
- search_case_library · 结果未知
- stock_quote · 结果未知
原文全文
展开原文 · 2,215 字
InnoCare Pharma (INCPF) announced that its novel TYK2 inhibitor, Fadeucravacitinib, achieved the primary endpoint in a registrational Phase III trial in patients with moderate-to-severe plaque psoriasis.
Psoriasis is a chronic, immune-mediated skin disease marked by red, scaly plaques and systemic inflammation, affecting millions worldwide and significantly impacting quality of life. Existing therapies often leave gaps in treatment, creating demand for new oral options.
Fadeucravacitinib is a potent and selective TYK2 allosteric inhibitor that blocks signaling pathways of inflammatory cytokines such as IL-23, IL-12, type 1 IFN, thereby targeting autoimmune and inflammatory processes. Beyond psoriasis, InnCcare is exploring development in other autoimmune conditions including cutaneous lupus erythematosus and Sjögren's syndrome.
The Phase III study was a randomized, double-blind, placebo-controlled, multicenter trial designed to evaluate efficacy, safety, and tolerability of Fadeucravacitinib. Results showed statistically significant and clinically meaningful improvement on the primary endpoint, with multiple secondary endpoints also met, demonstrating consistent benefit across measures. The therapy maintained a favorable safety profile, with no new safety signals identified.
CEO and Co-founder Jasmine Cui emphasized that meeting the primary endpoint represents a major step forward, noting the high demand for novel oral therapies in psoriasis. She added that InnoCare plans to advance regulatory filings to bring Fadeucravacitinib to patients with psoriasis and other autoimmune diseases.
INCPF has traded between $1.55 and $3.26 over the past year and is currently at the low end of its range, $1.55.
For comments and feedback contact: editorial@rttnews.com
Business News
July 25, 2026 02:46 ET The latest policy decision from the European Central Bank dominated the scene this week that was relatively slow for economics news flow. In the U.S., main highlights were the weekly initial jobless claims and new home sales data. In Europe, the ECB rate decision and the latest inflation figures from the U.K. drew attention. In Asia, results of a private sector survey from India were in focus.
Psoriasis is a chronic, immune-mediated skin disease marked by red, scaly plaques and systemic inflammation, affecting millions worldwide and significantly impacting quality of life. Existing therapies often leave gaps in treatment, creating demand for new oral options.
Fadeucravacitinib is a potent and selective TYK2 allosteric inhibitor that blocks signaling pathways of inflammatory cytokines such as IL-23, IL-12, type 1 IFN, thereby targeting autoimmune and inflammatory processes. Beyond psoriasis, InnCcare is exploring development in other autoimmune conditions including cutaneous lupus erythematosus and Sjögren's syndrome.
The Phase III study was a randomized, double-blind, placebo-controlled, multicenter trial designed to evaluate efficacy, safety, and tolerability of Fadeucravacitinib. Results showed statistically significant and clinically meaningful improvement on the primary endpoint, with multiple secondary endpoints also met, demonstrating consistent benefit across measures. The therapy maintained a favorable safety profile, with no new safety signals identified.
CEO and Co-founder Jasmine Cui emphasized that meeting the primary endpoint represents a major step forward, noting the high demand for novel oral therapies in psoriasis. She added that InnoCare plans to advance regulatory filings to bring Fadeucravacitinib to patients with psoriasis and other autoimmune diseases.
INCPF has traded between $1.55 and $3.26 over the past year and is currently at the low end of its range, $1.55.
For comments and feedback contact: editorial@rttnews.com
Business News
July 25, 2026 02:46 ET The latest policy decision from the European Central Bank dominated the scene this week that was relatively slow for economics news flow. In the U.S., main highlights were the weekly initial jobless claims and new home sales data. In Europe, the ECB rate decision and the latest inflation figures from the U.K. drew attention. In Asia, results of a private sector survey from India were in focus.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。